Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Neel R. Sodha & Frank W. Sellke. (2016) Reversal of Dabigatran with Idarucizumab. Expert Review of Cardiovascular Therapy 14:8, pages 889-893.
Read now
Read now
Victor F. Tapson. (2016) Diagnosis, prognosis and therapeutic management of acute pulmonary embolism. Hospital Practice 44:3, pages 164-172.
Read now
Read now
Jack Ansell. (2015) Is there a need for an alternative in the era of novel anticoagulants?. Expert Review of Cardiovascular Therapy 13:9, pages 967-970.
Read now
Read now
Giacomo Zoppellaro, Serena Granziera, Seena Padayattil Jose, Gentian Denas, Alessia Bracco, Sabino Iliceto & Vittorio Pengo. (2015) Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. Expert Opinion on Drug Safety 14:5, pages 683-695.
Read now
Read now
Gonzalo Barón-Esquivias, Francisco Fernández-Avilés, Felipe Atienza, Pablo Pastor Pueyo, Rocío Toro & Marcelo Sanmartín Fernández. (2015) Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 13:4, pages 341-353.
Read now
Read now
Articles from other publishers (29)
Shreya Arora, Shaalina Nair, Rishab Prabhu, Chaithanya Avanthika, Sharan Jhaveri, Shilpa Samayam, Maanya R Katta & Pahel Agarwal. (2021) Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome. Cureus.
Crossref
Crossref
Salma Abdeladim, Mahassine Elharrass, Ilham Bensahi, Amal Elouarradi & Mohamed Sabry. 2020. Handbook of Healthcare in the Arab World. Handbook of Healthcare in the Arab World
1
27
.
Salma Abdeladim, Mahassine Elharrass, Ilham Bensahi, Amal Elouarradi & Mohamed Sabry. 2021. Handbook of Healthcare in the Arab World. Handbook of Healthcare in the Arab World
2871
2896
.
Lumei Liu, Cole Rodman, Noah E. Worobetz, Jed Johnson, Charles Elmaraghy & Tendy Chiang. (2019) Topical biomaterials to prevent post-tonsillectomy hemorrhage. Journal of Otolaryngology - Head & Neck Surgery 48:1.
Crossref
Crossref
Paul P. Dobesh, Snehal H. Bhatt, Toby C. Trujillo & Krissa Glaubius. (2019) Antidotes for reversal of direct oral anticoagulants. Pharmacology & Therapeutics 204, pages 107405.
Crossref
Crossref
Stephanie Kustos & Pius Fasinu. (2019) Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update. Medicines 6:4, pages 103.
Crossref
Crossref
Antonia-Therese Kietaibl & Sibylle Kietaibl. (2019) New Hemostatic Agents: Perioperative Anesthetic Considerations. Current Pharmaceutical Design 25:19, pages 2158-2164.
Crossref
Crossref
Maureane Hoffman, Joshua N. Goldstein & Jerrold H. Levy. (2018) The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review. International Journal of Emergency Medicine 11:1.
Crossref
Crossref
Deborah K. Rose & Barak Bar. (2018) Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents. Journal of Stroke and Cerebrovascular Diseases 27:8, pages 2049-2058.
Crossref
Crossref
J.W. Eikelboom, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z. Boda, F. Christory, I. Gornik, G. Kėkštas, A. Kher, R. Komadina, O. Koval, G. Mitic, T. Novikova, E. Pazvanska, S. Ratobilska, J. Sütt, A. Winder & D. Zateyshchikov. (2018) Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia 120:4, pages 645-656.
Crossref
Crossref
Kyla M. Lara & Jonathan L. Halperin. 2018. Anticoagulation Therapy. Anticoagulation Therapy
217
238
.
Y. Song, Z. Wang, I. Perlstein, J. Wang, F. LaCreta, R.J.A. Frost & C. Frost. (2017) Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study. Journal of Thrombosis and Haemostasis 15:11, pages 2125-2137.
Crossref
Crossref
Andreas Zirlik & Christoph Bode. (2016) Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis 43:3, pages 365-379.
Crossref
Crossref
Masahiro Yasaka. 2017. Treatment of Non-vitamin K Antagonist Oral Anticoagulants. Treatment of Non-vitamin K Antagonist Oral Anticoagulants
25
39
.
Truman J. MillingJr.Jr. & Scott Kaatz. (2016) Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents. The American Journal of Medicine 129:11, pages S80-S88.
Crossref
Crossref
Truman J. MillingJrJr & Scott Kaatz. (2016) Preclinical and clinical data for factor Xa and “universal” reversal agents. The American Journal of Emergency Medicine 34:11, pages 39-45.
Crossref
Crossref
Savino Sciascia, Chary Lopez-Pedrera, Irene Cecchi, Clara Pecoraro, Dario Roccatello & Maria Josè Cuadrado. (2016) Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology 55:10, pages 1726-1735.
Crossref
Crossref
Jeffrey I. Weitz & John W. Eikelboom. (2016) Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis Research 146, pages 106-107.
Crossref
Crossref
Christian David Adams-Sánchez & Gabriel Jaime Tobón-García. (2016) Terapia con anticuerpos monoclonales en Cardiología y Medicina Interna. Revista Colombiana de Cardiología 23:4, pages 293-300.
Crossref
Crossref
James A. Reiffel, Jeffrey I. Weitz, Paul Reilly, Edvardas Kaminskas, Troy Sarich, Philip Sager & Jonathan Seltzer. (2016) NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American Heart Journal 177, pages 74-86.
Crossref
Crossref
Jack E. Ansell. (2016) Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. American Journal of Cardiovascular Drugs 16:3, pages 163-170.
Crossref
Crossref
Anand Patel, Richard P. Goddeau Jr & Nils Henninger. (2016) Newer Oral Anticoagulants: Stroke Prevention and Pitfalls. The Open Cardiovascular Medicine Journal 10:1, pages 94-104.
Crossref
Crossref
Jack E. Ansell. (2015) Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. Journal of Thrombosis and Thrombolysis 41:2, pages 248-252.
Crossref
Crossref
Richard C. Becker. (2015) The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes. Journal of Thrombosis and Thrombolysis 41:2, pages 273-278.
Crossref
Crossref
Hiroyuki Hamada, Shinichi Wada, Yohei Mima, Masahiro Yasaka, Takahiro Kuwashiro & Yasushi Okada. (2016) A case of thalamic hemorrhage which occurred during anticoagulant therapy with Xa inhibitor and expanded even after the administration of prothrombin complex concentrate. Nosotchu 38:6, pages 413-417.
Crossref
Crossref
Alessandro Di Minno, Gaia Spadarella, Emanuela Spadarella, Elena Tremoli & Giovanni Di Minno. (2015) Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. Thrombosis Research 136:6, pages 1074-1081.
Crossref
Crossref
Celeste B. Burness. (2015) Idarucizumab: First Global Approval. Drugs 75:18, pages 2155-2161.
Crossref
Crossref
Charles André. (2015) Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery. Arquivos de Neuro-Psiquiatria 73:8, pages 704-713.
Crossref
Crossref
Hiroyuki Hamada, Shinichi Wada, Yohei Mima, Masahiro Yasaka, Takahiro Kuwashiro & Yasushi Okada. (2015) Retraction:The onset of thalamic hemorrhage in Rivaroxaban in oral IX factor complex formulation administration, but showed a hematoma expansion case. Rinsho Shinkeigaku.
Crossref
Crossref